AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04637516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Animation program BlinkBlink
Description: Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
Study NCT04440059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 at a dose of 150mg PO QD
Study NCT01058083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 15 mg, Daily, 28 days
Study NCT01058083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 50 mg, Daily, 28 days
Study NCT01058083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 150 mg, Daily, 28 days
Study NCT01058083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 50 mg BID, Daily, 28 days
Study NCT01058083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral, 0 mg, daily, 28 days
Study NCT01951521 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost
Description: External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
Study NCT05523856 — intervention group
Intervention type: PROCEDURE
Intervention: Active Surveillance
Description: It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
Study NCT05523856 — intervention group
Intervention type: PROCEDURE
Intervention: Robot-Assisted Radical Prostatectomy
Description: It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
Study NCT05523856 — intervention group
Intervention type: RADIATION
Intervention: Intensity-Modulated Radiotherapy
Description: Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
Study NCT05523856 — intervention group
Intervention type: RADIATION
Intervention: Real-time brachytherapy
Description: Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
Study NCT01214681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and Amioca starch
Description: 12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
Study NCT01214681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize 260
Description: 23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
Study NCT01214681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: 12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
Study NCT01214681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hi-maize 260 and polydextrose
Description: 12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
Study NCT03437161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT either in the supine position with DIBH or in the prone position.
Study NCT02850718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Sildenafil
Description: 50 mg sildenafil sublingual wafer.
Study NCT02850718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sildenafil
Description: 50 mg oral sildenafil (Viagra)
Study NCT02291809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMUNE
Description: Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
Study NCT02291809 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: REMUNE
Description: Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
Study NCT03167047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Caudal epidural
Study NCT03167047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block
Description: Peripheral nerve block
Study NCT03167047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standarising intraoperative pain relief
Description: All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
Study NCT02325830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: Percutaneous mitral valve repair
Study NCT00428025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: 100 mg diclofenac rectal suppository
Study NCT00428025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: similar shape and size suppository
Study NCT03023423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab 1200 mg intravenously.
Study NCT03023423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg intravenously.
Study NCT03454659 — intervention group
Intervention type: PROCEDURE
Intervention: Craniotomy
Description: Extracting the part of the sculpt
Study NCT01498783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
Study NCT05092698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (cholecalciferol)
Description: Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
Study NCT05092698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Herbal oil
Description: Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
Study NCT01084993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
Study NCT01084993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 70 U/kg
Study NCT05612646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points.
Study NCT05612646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine nursing and fake acupressure
Description: control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
Study NCT02930252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niti-S Biliary ComVi Stent
Description: Endoscopic placement of biliary fully covered metal stents
Study NCT02930252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Niti-S stent (D type)
Description: Endoscopic placement of biliary uncovered metal stent
Study NCT04431219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIS1
Description: LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
Study NCT00352378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Description: Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
Study NCT04141722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight sleep
Description: Participant sent home to sleep overnight wearing PSG.
Study NCT04141722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake
Description: Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
Study NCT00764270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
Study NCT00764270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
Study NCT00428337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1233
Description: DNA-HIV-recombinant vaccine
Study NCT00428337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN32
Description: HIV-recombinant viral vaccine
Study NCT01198847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary, physical activity and sleeping
Description: The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support
Study NCT01198847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary, physical activity and sleeping
Description: The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological and neurophysiological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological and neurophysiological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment 1
Description: Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experiment 1
Description: Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment 2
Description: Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experiment 2
Description: Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment 3
Description: Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experiment 3
Description: Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment 4
Description: Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners.
Study NCT03094624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experiment 4
Description: Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners.
Study NCT00101998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Study NCT00101998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00101998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02171247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: Isovue 370 is a contrast agent with increased iodine concentration.
Study NCT02171247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: Visipaque 320 is standard protocol.
Study NCT02592707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide tetraxetan
Description: Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
Study NCT02592707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino acid solution
Description: Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)
Study NCT02592707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetic
Description: To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
Study NCT03190629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux hemodialysis
Description: Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
Study NCT03190629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On line-hemodiafiltration
Description: Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
Study NCT04295850 — intervention group
Intervention type: DRUG
Intervention: Aspirin 81 mg
Description: Aspirin 81mg daily PO
Study NCT00581841 — intervention group
Intervention type: OTHER
Intervention: Gait analysis, knee x-ray, and knee MRI
Description: Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.